The University of Oxford, in partnership with Alamar Biosciences, is pleased to announce a targeted funding initiative to support high-impact translational immunology research.
This programme will support three selected projects with subsidised access to the NULISAseq™ Inflammation Panel 250, delivered via the University of Oxford Multiomics Platforms Facility.
The panel enables ultra-sensitive, multiplexed quantification of low-abundance cytokines, chemokines, and immune mediators – unlocking biological insights not accessible with conventional approaches.
This initiative aims to:
We welcome applications across the Oxford research community, including:
We particularly encourage proposals with clear translational potential, especially those aligned with well-characterised cohorts or that could scale into larger studies.
Do you have questions? Please reach out to tburley@alamarbio.com.
Terms and Conditions
Eligibility and Requirements:
To be eligible, applicants must meet all of the following criteria:
– Have attended the Alamar Biosciences User Group Meeting seminar and/or workshop held on 15 April 2026 at the University of Oxford.
– Be actively enrolled at an academic institution, or employed at a research facility in a research capacity, with access to relevant samples.
– Be 18 years of age or older at the time of application.
Members of the immediate families of Alamar Biosciences employees and directors, and persons living in the same household as such individuals, are ineligible to apply.
Award Details:
– 3 awards are available.
– Each award consists of one NULISAseq™ Inflammation Panel 250 per project (up to 86 samples).
– Analysis will be performed by the Oxford Multiomics Platforms Facility.
– Analysis must commence within six (6) weeks of award notification. Extensions may be granted at Alamar’s sole discretion upon written request.
Cost Structure:
This programme is heavily subsidised. The Inflammation 250 panels have been internally validated and confirmed to perform within expected specifications; accordingly, no cost is attributed to the panels themselves.
Successful applicants will be required to cover the following costs only:
– £3,000 per plate (sequencing costs)
– Associated service fees from the Oxford Multiomics Platforms Facility, charged at cost.
Applicants are encouraged to confirm that institutional budget availability for these costs is in place prior to submitting an application.
Award Selection Criteria:
– Sample matrix: No restriction (e.g. plasma, serum, CSF, tissue, or other).
– Applications will be jointly reviewed by the University of Oxford and Alamar Biosciences.
– Grant submissions must be received by 11:59 PM British Summer Time on Friday, 01 May 2026.
Award Details:
Successful applicants will be notified by email no later than Friday, 15 May 2026. All applicants will receive confirmation that their submission was received.
Publication of Results:
All grant submissions are confidential to the individual submitter and will not be published or distributed to third parties.
Upon project completion, each grant recipient agrees to participate in one of the following activities relating to the specific project, within 12 months of project completion, with details to be mutually agreed in good faith between Alamar and the recipient:
– Local seminar
– Webinar
– Case study
– Blog post
– Poster presentation
Each recipient agrees that Alamar shall have the right to use de-identified data from the project in application notes or marketing literature.
Eligibility and Requirements:
To be eligible, applicants must meet all of the following criteria:
– Have attended the Alamar Biosciences User Group Meeting seminar and/or workshop held on 15 April 2026 at the University of Oxford.
– Be actively enrolled at an academic institution, or employed at a research facility in a research capacity, with access to relevant samples.
– Be 18 years of age or older at the time of application.
Members of the immediate families of Alamar Biosciences employees and directors, and persons living in the same household as such individuals, are ineligible to apply.
Miscellaneous:
Alamar Biosciences, Inc. is the sole sponsor of this grant programme. No purchase is necessary to enter or win. By applying, each applicant agrees to these terms and conditions and to Alamar’s processing of their personal data in accordance with Alamar’s privacy policy, available at alamarbio.com/privacy.
This grant programme is void where prohibited or restricted by law. The grant recipient, or their applicable institution, is solely responsible for any tax liability arising from acceptance of the services provided.
This is not a cash grant; recipients have no option to receive any cash payment or alternative award in lieu of the services offered. The grant may not be transferred or assigned to any third party.
Services will be provided subject to Alamar’s standard terms and conditions for TAP service projects, as amended from time to time. Alamar makes no warranty, representation, or guarantee, express or implied, with respect to the services provided, including without limitation their fitness for a particular purpose.
Alamar reserves the right, in its sole discretion, to cancel, modify, or suspend the grant programme at any time.
These terms and conditions are governed by the laws of the State of Delaware, USA, without regard to its conflict of law provisions.
CSO
Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.
CFO
Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.